Jie Zhou1,2, Jing Hou1,2, Jun Rao2,3, Conghui Zhou2,4, Yunlong Liu5, Wenxi Gao1,2. 1. Department of Urology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei, People's Republic of China. 2. Hubei Province Academy of Traditional Chinese Medicine, Wuhan, Hubei, People's Republic of China. 3. Clinical Laboratory, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei, People's Republic of China. 4. Department of Pharmaceutical Sciences, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, Hubei, People's Republic of China. 5. Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, People's Republic of China.
Abstract
BACKGROUND: β-Glucosidase (β-Glu) can activate amygdalin to kill prostate cancer cells, but the poor specificity of this killing effect may cause severe general toxicity in vivo, limiting the practical clinical application of this approach. MATERIALS AND METHODS: In this study, starch-coated magnetic nanoparticles (MNPs) were successively conjugated with β-Glu and polyethylene glycol (PEG) by chemical coupling methods. Cell experiments were used to confirm the effects of immobilized β-Glu on amygdalin-mediated prostate cancer cell death in vitro. Subcutaneous xenograft models were used to carry out the targeting experiment and magnetically directed enzyme/prodrug therapy (MDEPT) experiment in vivo. RESULTS: Immobilized β-Glu activated amygdalin-mediated prostate cancer cell death. Tumor-targeting studies showed that PEG modification increased the accumulation of β-Glu-loaded nanoparticles in targeted tumor tissue subjected to an external magnetic field and decreased the accumulation of the nanoparticles in the liver and spleen. Based on an enzyme activity of up to 134.89 ± 14.18mU/g tissue in the targeted tumor tissue, PEG-β-Glu-MNP/amygdalin combination therapy achieved targeted activation of amygdalin and tumor growth inhibition in C57BL/6 mice bearing RM1 xenografts. Safety evaluations showed that this strategy had some impact on liver and heart function but did not cause obvious organ damage. CONCLUSION: All findings indicate that this magnetically directed enzyme/prodrug therapy strategy has the potential to become a promising new approach for targeted therapy of prostate cancer.
BACKGROUND: β-Glucosidase (β-Glu) can activate amygdalin to kill prostate cancer cells, but the poor specificity of this killing effect may cause severe general toxicity in vivo, limiting the practical clinical application of this approach. MATERIALS AND METHODS: In this study, starch-coated magnetic nanoparticles (MNPs) were successively conjugated with β-Glu and polyethylene glycol (PEG) by chemical coupling methods. Cell experiments were used to confirm the effects of immobilized β-Glu on amygdalin-mediated prostate cancer cell death in vitro. Subcutaneous xenograft models were used to carry out the targeting experiment and magnetically directed enzyme/prodrug therapy (MDEPT) experiment in vivo. RESULTS: Immobilized β-Glu activated amygdalin-mediated prostate cancer cell death. Tumor-targeting studies showed that PEG modification increased the accumulation of β-Glu-loaded nanoparticles in targeted tumor tissue subjected to an external magnetic field and decreased the accumulation of the nanoparticles in the liver and spleen. Based on an enzyme activity of up to 134.89 ± 14.18mU/g tissue in the targeted tumor tissue, PEG-β-Glu-MNP/amygdalin combination therapy achieved targeted activation of amygdalin and tumor growth inhibition in C57BL/6 mice bearing RM1 xenografts. Safety evaluations showed that this strategy had some impact on liver and heart function but did not cause obvious organ damage. CONCLUSION: All findings indicate that this magnetically directed enzyme/prodrug therapy strategy has the potential to become a promising new approach for targeted therapy of prostate cancer.
Authors: Jasmina Makarević; Igor Tsaur; Eva Juengel; Hendrik Borgmann; Karen Nelson; Christian Thomas; Georg Bartsch; Axel Haferkamp; Roman A Blaheta Journal: Life Sci Date: 2016-01-29 Impact factor: 5.037
Authors: Jasmina Makarević; Jochen Rutz; Eva Juengel; Silke Kaulfuss; Michael Reiter; Igor Tsaur; Georg Bartsch; Axel Haferkamp; Roman A Blaheta Journal: PLoS One Date: 2014-08-19 Impact factor: 3.240
Authors: Karolin Roemhild; Helena C Besse; Bi Wang; Quim Peña; Qingxue Sun; Daiki Omata; Burcin Ozbakir; Clemens Bos; Hans W Scheeren; Gert Storm; Josbert M Metselaar; Haijun Yu; Ruth Knüchel-Clarke; Fabian Kiessling; Chrit T W Moonen; Roel Deckers; Yang Shi; Twan Lammers Journal: Theranostics Date: 2022-06-06 Impact factor: 11.600
Authors: Gema Vivo-Llorca; Ángela Morellá-Aucejo; Alba García-Fernández; Paula Díez; Antoni Llopis-Lorente; Mar Orzáez; Ramón Martínez-Máñez Journal: Int J Nanomedicine Date: 2022-01-26